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We have previously demonstrated that mitogen-activated protein kinase phosphatase 1, Mkp1, is expressed in the
developing and rat adult substantia nigra and striatum, where it promotes the growth of nigral dopaminergic
neurons. Mkp1 may therefore have therapeutic potential for Parkinson’s disease. In the present study, we have
assessed the expression of Mkp1 and TH in the substantia nigra and striatum of parkinsonian rat models. Expression
was measured at 4 and 10 days post-lesion in the 6-hydroxydopamine (6-OHDA) medial forebrain bundle lesion model
and after 4, 10 and 28 days in the 6-OHDA striatal lesion model. Our results show that Mkp1 expression was transiently
up-regulated in the substantia nigra at 4 days post-6-OHDA administration in the two models while TH expression
was decreased at the later time-points examined. These data suggest that Mkp1 may play a role in counteracting
the neurotoxic effects of 6-OHDA in nigral dopaminergic neurons.
Keywords: Parkinson’s disease; 6-hydroxydopamine; MAP kinase phosphatase 1; MKP1Introduction
6-hydroxydopamine (6-OHDA) is a dopamine analogue
which selectively kills dopaminergic neurons and has
been extensively used to model Parkinson’s disease (PD)
in animals. Unilateral 6-OHDA injection in the medial
forebrain bundle (MFB) of rats induces a near complete
nigrostriatal degeneration and a resultant motor impair-
ment reminiscent of that observed in Parkinson’s disease
(Ungerstedt 1968; Ungerstedt and Arbuthnott 1970).
However, as MFB injection of 6-OHDA results in an
acute loss of dopaminergic neurons that also affects the
mesocorticolimbic pathways (Breysse et al. 2007), alter-
native models have been developed. Specifically, four
unilateral injections of 6-OHDA along the rostro-caudal
axis of the striatum results in a progressive loss of ap-
proximately 80% of nigral dopaminergic neurons and
motor impairments that more closely resembles the pro-
gressive nature of PD (Kirik et al. 1998).
The apparent lag between the loss of dopaminergic neu-
rons and the appearance of motor symptoms in PD has
been attributed to sprouting of remaining dopaminergic* Correspondence: a.toulouse@ucc.ie
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Specifically, surviving dopaminergic neurons from 6-
OHDA-treated animals have been shown to undergo
axonal sprouting to maintain dopaminergic terminal
density as a compensatory response (Stanic et al. 2003).
However, the molecular mechanisms mediating this
compensatory sprouting are poorly understood. We
and others have recently shown that overexpression of
the mitogen activated protein kinase phosphatase-1
(Mkp1) promotes the growth and branching of devel-
oping cortical (Jeanneteau et al. 2010) and midbrain
dopaminergic neurons in vitro, and that Mkp1 expres-
sion can be modulated by 6-OHDA (Collins et al.
2013). Mitogen-activated protein kinase phosphatases
(MKPs) provide a negative feedback mechanism for
regulating MAPK activity (including p38, JNK and
ERK) by de-phosphorylating these kinases (Farooq and
Zhou 2004). Mkp1 has also been shown to offer neuro-
protection in models of Huntington’s disease (HD)
(Taylor et al. 2013), and to prevent neuronal death in a
model of acute cerebral infarction (Koga et al. 2012). In
light of these findings, the aim of the present study was
to assess Mkp1 expression in the striatum and midbrain
in the 6-OHDA MFB model and the four-site 6-OHDA
striatal lesion models of PD.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Striatal and MFB 6-OHDA lesion surgery
Date-mated Sprague–Dawley rats were provided by the
Biological Services Unit, UCC. All scientific procedures
were performed under a license issued by the Depart-
ment of Health and Children (Ireland) and in accord-
ance with the European Communities Council Directive
(86/609/EEC). Ethical approval was granted by the Ani-
mal Experimentation Ethics Committee, UCC (AEEC).
Sixty male rats (220–260 g) were used (n = 5 for each of
saline and 6-OHDA intrastriatal injection, in groups
sacrificed at 4, 10 or 28 days; n = 5 for each of saline and
6-OHDA MFB injection, in groups sacrificed at 4 or
10 days; n = 5 for intact control groups for each of the 2
experiments). 6-OHDA hydrobromide containing 0.01%
ascorbic acid as a stabiliser (Sigma-Aldrich) was resus-
pended in saline solution and injected in test animals.
Control animals were injected with the resuspension so-
lution alone (saline). Right-sided unilateral striatal and
MFB 6-OHDA lesion surgeries were previously de-
scribed (Gavin et al. 2014).
Immunohistochemistry
Serial sections (30 μm) were prepared from fixed and
cryoprotected SN from 3 animals using a freezing sledge
microtome. Following quenching of endogenous perox-
idase activity (0.3% H2O2-10% methanol in dH2O) and
blocking (3% normal horse or goat serum in 0.2%
Triton-X-TBS), the sections were incubated overnight with
primary antibodies against TH (1:1000; mouse monoclo-
nal; Millipore) or Mkp1 (1:200; rabbit polyclonal; Santa
Cruz Biotechnology) diluted in 1% normal horse or goat
serum. The sections were incubated with biotinylated sec-
ondary antibodies (Vectastain® ABC Kit peroxidase mouse
or rabbit IgG), followed by a streptavidin–biotin–horse-
radish peroxidase solution (Vector Laboratories). Immu-
nolabelling was revealed by incubating the sections in a
0.05% solution of diaminobenzidine tetrahydrochloride-
0.015% H2O2 in TBS or using the Vector Laboratories SG
blue-grey. Sections were imaged on a Olympus Ax70
microscope.
mRNA extraction and RT-QPCR
The RNA samples were obtained from Gavin et al. (2014).
At 0, 4, 10 or 28 days after 6-OHDA or saline administra-
tion to the right striatum or MFB, left and right substantia
nigra and striatum were dissected and RNA extracted and
quantified. Total RNA (1 μg) was reverse-transcribed using
Affinity Script reverse-transcriptase (Agilent Technologies),
for 45 min at 45˚C, in a 20 μl reaction containing 5 mM
dNTPs, 10 mM DTTand 10 μM random hexamer primers.
2 μl of cDNA template was used to amplify each of the nor-
malising reference genes, glyceraldehyde 3-phosphate de-
hydrogenase (Gapdh), succinate dehydrogenase complex,subunit A (Sdha) and ubiquitin C (Ubqc), in 20 μl reac-
tions using Brilliant III Ultra-Fast SYBR® Green QPCR
Master Mix reagents (Agilent Technologies) containing
150 nM each of forward and reverse primers using con-
ditions previously described (Gavin et al. 2014). Gapdh,
Sdha and Ubqc amplification products were verified as
accurate via melting-curve analysis of the completed
PCR reaction (melting temperatures of 83.5°C, 80°C
and 85°C, respectively). For Mkp1, 2 μl of cDNA was
amplified in a 20 μl PCR reaction using Brilliant III
Ultra-Fast QPCR Master Mix reagents (Agilent Tech-
nologies) containing 150 nM each of forward (5’-CTAC
TACAACGGTCTTCAA-3’) and reverse primers (5’-CT
CTCCCAGAGTTATTGC-3’) and 300 nM of a FAM/
BHQ1 dual-labelled hybridization probe (5’-FAM-TTC
CCTGTCTCCATCCCTGT-BHQ1-3’, Eurofins). For TH
amplification, previously described conditions, were used
(Gavin et al. 2014). The initial quantities of cDNA in each
PCR reaction were determined by comparison to standard
curves that were generated by serial dilutions of reverse-
transcribed RNA purified from either the striatum or SN.
Values for each gene of interest were normalised to a geo-
metrical mean of the three reference genes. Each reaction
was repeated 3 times and amplifications were performed
in triplicate each time.
Statistical analysis
Each data point represents grouped data from 3 separate
RNA preparations, taken from 4 animals. One-way
ANOVA with post-hoc Tukey’s test were used to deter-
mine significance. Data are expressed as mean with
standard errors and deemed significant when p <0.05.
Results
Mkp1 is expressed in adult rat SN dopaminergic neurons
We have previously demonstrated that Mkp1 is expressed
in the developing midbrain, including dopaminergic neu-
rons, and that it is also expressed in the adult SN (Collins
et al. 2013). In order to further characterize the adult
expression of Mkp1, particularly in dopaminergic neu-
rons, we performed an immunohistochemistry for TH
and Mkp1 in the adult SN. Representative images in
Figure 1 show that TH+ (Figure 1a,b) and Mkp1+ cells
(Figure 1c,d) were evident in the adult rat SNpc and
SNpr under basal conditions. Double-labelling experi-
ments revealed that TH+ dopaminergic neurons express
Mkp1 (Figure 1e,f ) indicating a potential regulatory
role for Mkp1 in these cells. In particular, Mkp1 expres-
sion was prominent in the soma rather than in the neur-
ites of these cells (Figure 1f). Mkp1 is more broadly
expressed, and is also present in TH- cells (Figure 1f).
Negative controls where primary antibodies were omitted
showed no evidence of staining (data not shown). This
suggests that even though some dopaminergic neurons
Figure 1 Mkp1 is expressed in dopaminergic neurons in the adult rat SN. Representative photomicrograph showing (a, b) TH expression
(brown), (c, d) Mkp1 expression (brown) and (e, f) Mkp1 expression (brown) in TH+ (blue/black) dopaminergic neurons throughout the adult rat
SN under basal conditions. (f) Co-localisation in the SNpc. Red arrows indicate TH+ (blue/black), green arrows indicate Mkp1+ (brown) cells while
the blue arrow indicates double labelling of Mkp1+/TH+ cells. Scale bars =100 μm (a, c, e) or 50 μm (b, d, f).
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sible to detect Mkp1 mRNA expression from surrounding
cells.
Mkp1 mRNA expression is transiently increased in the SN
following unilateral 6-OHDA MFB or striatal lesions
The 6-OHDA-induced lesions resulted in a significant
ipsilateral dopaminergic neuronal depletion accompan-
ied by increased contralateral amphetamine-induced ro-
tations (Gavin et al. 2014). To analyse the temporal
dynamics of dopaminergic neuronal loss in both the
MFB and striatal 6-OHDA lesion models, Th mRNA ex-
pression was quantified in the SN at 0, 4 and 10 days
post-6-OHDA MFB lesion (Figure 2a) or at 0, 4, 10, and
28 days post-6-OHDA striatal lesion (Figure 2d, datafrom Gavin et al., 2014). Our results demonstrated that
right-sided unilateral 6-OHDA injections to the right MFB
resulted in a reduction in Th mRNA expression in the ipsi-
lateral SN at 4 and 10 days post-lesion compared to saline-
treated animals at the same time point (p < 0.01; Figure 2a).
Interestingly, Mkp1 mRNA expression increased at 4 days
post-lesion in the ipsilateral SN compared to saline-treated
animals at the same time point (p < 0.01; Figure 2b) and
returned to baseline by 10 days post-lesion (Figure 2b).
There was no significant change detected in Mkp1 mRNA
expression in the ipsilateral (Figure 2c) striatum after 6-
OHDA administration to the MFB compared to saline-
treated animals at the same time point.
Unilateral 6-OHDA injections to the right striatum re-
sulted in a reduction in Th mRNA expression in the
Figure 2 Mkp1 mRNA expression is transiently increased in the SN following unilateral 6-OHDA MFB or striatal lesions. qRT-PCR of (a)
Th, (b) Mkp1 mRNA in the ipsilateral SN and (c) Mkp1 mRNA in the ipsilateral striatum at 0, 4, and 10 days after administration of 6-OHDA or saline
into the right MFB. qRT-PCR of (d) Th, (e) Mkp1 mRNA in the ipsilateral SN and (f) Mkp1 mRNA in the ipsilateral striatum at 0, 4, 10 and 28 days
after administration of 6-OHDA or saline into the right striatum. ** p < 0.01 vs. saline-treated control at the same time-point; one-way ANOVA with
post-hoc Tukey’s test (n = 4 animals). Data are expressed as mean with standard errors.
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lesion compared to saline-treated animals at the same
time point (p < 0.01; Figure 2d). We observed no re-
duction in Th mRNA expression at 4 days post-lesion
(Figure 2d) unlike that observed in the MFB model
(Figure 2a). There was an increase in Mkp1 expression
at 4 days post-lesion compared to saline-treated ani-
mals at the same time point (p < 0.01; Figure 2e). This
increase returned to baseline by 10 days post-lesion
(Figure 2e). There was no change detected in Mkp1
mRNA expression in the ipsilateral (Figure 2f ) stri-
atum after 6-OHDA administration to the striatum
compared to saline-treated animals at the same time
point.
Discussion
This study examined Mkp1 mRNA expression in the SN
and striatum of the adult rat nigrostriatal pathway in the
MFB and striatal 6-OHDA lesion models of PD. It has
been reported that these lesion paradigms lead to differ-
ent spatiotemporal patterns of nigrostriatal cell body and
terminal degeneration. In terms of the dopaminergic cell
bodies in the SN, both the striatal and MFB lesion have
been shown to induce neuronal loss that is first apparent
at 72 h post-lesioning and worsens thereafter (Walsh
et al. 2011). The MFB lesion paradigm is generally
recognised as a more severe phenotype representing the
end stages of PD with near complete neuronal depletion
in the SN while the striatal model leads to a more subtle
and progressive degeneration reminiscent of the early
stages of the disease (Bove and Perier 2012). This is ingeneral agreement with our quantitative PCR data
showing a ~60% reduction in Th mRNA in the MFB
lesion model and a non-significant 20% reduction in
the striatal lesion model at 4 days post-lesion becom-
ing more pronounced after 10 and 28 days. In the
current study, we report an up-regulation of Mkp1
mRNA expression in the SN in both the MFB and the
striatal 6-OHDA lesion models at 4 days post-lesion,
which returned to baseline by 10 days post-lesion.
There was no up-regulation of Mkp1 in the contralat-
eral striatum or SN (data not shown), or in the ipsilat-
eral striatum, indicating that the up-regulation of
Mkp1 mRNA was specific to the 6-OHDA-induced
changes in the SN. As Mkp1 mRNA is increased at
4 days post-lesion, which precedes the degeneration of
dopaminergic neurons at day 10 in the striatal model,
it is plausible that the progressive degeneration in this
model may allow a window of opportunity for Mkp1 to
attempt to rescue dopaminergic nerve terminals. The
neurodegeneration observed in the MFB model is of
greater magnitude and is usually accepted as occurring
at earlier time-points following 6-OHDA infusion.
Considering the 50% increase in Mkp1 expression ob-
served in a severely depleted SN, it is possible that this
increase represents the tissue’s attempt to prevent neu-
rodegeneration. We cannot rule out the possibility that
changes in Mkp1 expression are provided by other cell
types, as Mkp1 has previously been shown to be up-
regulated in microglia after treatment with lipopolysac-
charide, albeit in cortical tissue (Camps et al. 2000).
We have previously shown that 6-OHDA up-regulates
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cephalon samples while it is specifically down-regulated in
6-OHDA-treated dopaminergic neurons cultured in vitro
(Collins et al. 2013), suggesting that up-regulation of
Mkp1 expression detected in the present study may occur
mostly in glial cells. It is also tempting to speculate that
Mkp1 may be up-regulated in both SN dopaminergic neu-
rons and microglia in an attempt at cellular neuroprotec-
tion following exposure to 6-OHDA. Indeed, strategies
that increase Mkp1 in the central nervous system (CNS)
have been shown to be neuroprotective in a number of
animal models of neurodegenerative and inflammatory
CNS insults (Eljaschewitsch et al. 2006; Koga et al. 2012;
Taylor et al. 2013).
The molecular mechanisms that lead to the induction
of Mkp1 following 6-OHDA insult are unclear, however
it may result from a MAPK-Mkp feedback loop (Camps
et al. 2000). Specifically, it has been previously demon-
strated that unilateral administration of 6-OHDA to the
MFB resulted in a significant and sustained increase in
the level of phospho-p38 in dopaminergic neurons in
the ipsilateral SN for at least 10 days post-lesion (Crotty
et al. 2008). Mkp1 forms a negative feedback loop to
control p38 activity, and consequently the expression
of Mkp1 is induced by stimuli that activate MAPK
pathways, including p38 (Camps et al. 2000). Given
that 6-OHDA induces phospho-p38 expression in
dopaminergic neurons in vitro (Collins et al. 2013) and
in vivo (Crotty et al. 2008), it is possible that this also
is accompanied by an induction of Mkp1 in an attempt
to down-regulate p38 activation. In rodents, this com-
pensatory mechanism may be, at least in part, the reason
that striatal dopaminergic terminal density is main-
tained at normal levels until >70% of nigral cells are
lost (Finkelstein et al. 2000; Stanic et al. 2003). Thus,
Mkp1, through its regulation of p38 activation, may be
critically involved in inducing or maintaining this com-
pensatory mechanism.
This study demonstrates that the expression of Mkp1
mRNA is regulated in a precise spatio-temporal pattern
following 6-OHDA insult to the MFB and/or striatum.
These results raise the possibility that the sprouting of
dopaminergic nerve terminals in the striatum following
exposure to 6-OHDA may be mediated by an up-
regulation of Mkp1. In the wider context of PD, these
data suggest that up-regulation of Mkp1 in the parkin-
sonian SN may occur at early stages of the disease in an
attempt at endogenous neuroprotection, but that at later
stages of the disease, when these Mkp1 inductive mecha-
nisms fail, a more rapid degeneration of dopaminergic
neurons occurs. Therefore, it will be important to study
the relative levels of Mkp1 at different stages of PD, as
strategies aimed at augmenting Mkp1 expression may be
therapeutically beneficial.Abbreviations
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